These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1834359)

  • 1. Antiemetic activity of the new 5-HT3 antagonist DAU 6215 in animal models of cancer chemotherapy and radiation.
    Sagrada A; Turconi M; Bonali P; Schiantarelli P; Micheletti R; Montagna E; Nicola M; Algate DR; Rimoldi EM; Donetti A
    Cancer Chemother Pharmacol; 1991; 28(6):470-4. PubMed ID: 1834359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog.
    Fitzpatrick LR; Lambert RM; Pendley CE; Martin GE; Bostwick JS; Gessner GW; Airey JE; Youssefyeh RD; Pendleton RG; Decktor DL
    J Pharmacol Exp Ther; 1990 Aug; 254(2):450-5. PubMed ID: 2166791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis.
    Haga K; Inaba K; Shoji H; Morimoto Y; Fukuda T; Setoguchi M
    Jpn J Pharmacol; 1993 Nov; 63(3):377-83. PubMed ID: 8107329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ondansetron. Therapeutic use as an antiemetic.
    Milne RJ; Heel RC
    Drugs; 1991 Apr; 41(4):574-95. PubMed ID: 1711961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin antagonists: a new class of antiemetic agents.
    Hesketh PJ; Gandara DR
    J Natl Cancer Inst; 1991 May; 83(9):613-20. PubMed ID: 1850806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-nausea effects and pharmacokinetics of ondansetron, maropitant and metoclopramide in a low-dose cisplatin model of nausea and vomiting in the dog: a blinded crossover study.
    Kenward H; Elliott J; Lee T; Pelligand L
    BMC Vet Res; 2017 Aug; 13(1):244. PubMed ID: 28814338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist.
    Fukuda T; Setoguchi M; Inaba K; Shoji H; Tahara T
    Eur J Pharmacol; 1991 Apr; 196(3):299-305. PubMed ID: 1654255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
    Fraschini G
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
    Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
    J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
    Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
    J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog.
    Yoshida N; Omoya H; Ito T
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1159-65. PubMed ID: 1532032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative trials of ondansetron versus metoclopramide in the prevention of acute cisplatin-induced emesis.
    Hesketh PJ
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):33-40. PubMed ID: 1387248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist.
    Ozaki A; Sukamoto T
    Gen Pharmacol; 1999 Sep; 33(3):283-8. PubMed ID: 10480662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.
    Baltzer L; Kris MG; Tyson LB; Rigas JR; Vreeland F; Pisters KM
    Cancer; 1993 Nov; 72(9):2695-9. PubMed ID: 8402492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
    Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
    J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
    Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
    Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and preclinical antiemetic properties of ondansetron.
    Tyers MB
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):1-8. PubMed ID: 1387245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.